Close Menu

NEW YORK (360Dx) – Seville, Spain-based Universal Diagnostics said last week that it is participating in a clinical study at a network of hospitals in London to validate its large-scale screening test for detection of early-stage colorectal cancer and adenomas.

The test uses mass spectrometry and a panel of 30 small-molecule metabolomics biomarkers, including lipids and amino acids, to measure metabolites in blood samples that are linked to the presence of colorectal cancer and precancerous cells, or adenomas.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.